O1‐09‐05: UPDATE ON THE SAFETY AND TOLERABILITY OF GANTENERUMAB IN THE ONGOING OPEN‐LABEL EXTENSION OF THE SCARLET ROAD STUDY IN PATIENTS WITH PRODROMAL ALZHEIMER'S DISEASE AFTER APPROXIMATELY 2 YEARS OF STUDY DURATION-Reference-Cited by-同舟云学术

O1‐09‐05: UPDATE ON THE SAFETY AND TOLERABILITY OF GANTENERUMAB IN THE ONGOING OPEN‐LABEL EXTENSION OF THE SCARLET ROAD STUDY IN PATIENTS WITH PRODROMAL ALZHEIMER'S DISEASE AFTER APPROXIMATELY 2 YEARS OF STUDY DURATION

Published:2006-07 Issue:7S_Part_4 Volume:14 Page:
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Andjelkovic Mirjana¹,Abi-Saab Danielle¹,Delmar Paul¹,Pross Nathalie¹,Voyle Nicola²,Klein Gregory¹,Mertes Michaela¹,Ristic Smiljana¹,Martenyi Ferenc¹,Fontoura Paulo¹,Doody Rachelle³⁴

Affiliation:

1. F. Hoffmann-La Roche LtdBaselSwitzerland

2. Roche Products LtdWelwyn Garden CityUnited Kingdom

3. Product Development NeuroscienceF. Hoffmann-La Roche LtdBaselSwitzerland

4. Genentech, Inc.South San FranciscoCAUSA

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1016/j.jalz.2018.06.2382

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease;Alzheimer's Research & Therapy;2022-11-29

2. New Perspectives for Treatment in Alzheimer’s Disease;Pharmacological Treatment of Alzheimer's Disease;2022

3. What works and what does not work in Alzheimer’s disease? From interventions on risk factors to anti‐amyloid trials;Journal of Neurochemistry;2020-05-09

4. Progress and perspectives of brain-targeting lipid-based nanosystems via the nasal route in Alzheimer’s disease;European Journal of Pharmaceutics and Biopharmaceutics;2020-03

5. Cerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways;Nature Reviews Neurology;2019-12-11